SUBSCRIBE
SUBSCRIBE
News   Policy

Akorn, Inc. Responds to FDA Draft Guidance for Industry on Bioequivalence Recommendation for Vancomycin HCl

December 16, 2008 | 
1 min read
LAKE FOREST, Ill.--(BUSINESS WIRE)--Akorn, Inc. (NASDAQ: AKRX) today provided the following response regarding FDA’s draft guidance on vancomycin hydrochloride (HCl) capsules.
Regulatory
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Podcast
UniQure’s Delay, REGENXBIO’s Rejection Explained, Sarepta’s Ingram Steps Down, More
March 4, 2026
 · 
1 min read
 · 
Heather McKenzie
Handmade signboard with Closed inscription and striped rope hanging on pin on bright red background
Company closure
Bespoke Startup EveryONE Folds 1 Week After Plausible Mechanism Guidance
March 4, 2026
 · 
2 min read
 · 
Tristan Manalac
Composite contemporary collage statue of justice themis femida on the background of the target as the concept and idea of justice and law. High quality photo
Patents
Moderna Notches Much-Needed Win in COVID-19 Patent Spat With Roivant
March 4, 2026
 · 
2 min read
 · 
Tristan Manalac
Man walking on a long wavy path with flag at the end, persistence, determination and ultimate business success - 3D Render
Rare disease
UniQure Eyes Phase 3 for Huntington’s Gene Therapy Despite Makary’s Apparent Criticism
March 2, 2026
 · 
3 min read
 · 
Heather McKenzie